Abstract |
The present study aims to assess the feasibility and the effectiveness of a second-line Fotemustine chemotherapy in patients with recurrent Glioblastoma after standard primary treatment. Between 2005 and 2007, 50 patients with relapsed malignant glioma (median age=56.8 years; median KPS=90) underwent a second-line chemotherapy with Fotemustine. Selected patients were previously treated with a standard 60 Gy Radiotherapy course and Temozolomide Chemotherapy. Patients were stratified into classes according to the prognostic Recursive Partition Analysis. Endpoints of the study were Progression Free Survival at 6 months, duration of Objective Response and Stabilization, Overall Survival and toxicity. At analysis, 36 patients were dead and 14 were alive. Median follow-up from primary diagnosis was 26.6 months. The Efficacy control of the disease was 62%. PFS was 6.1 months; PFS-6 was 52% and median overall survival from primary diagnosis was 24.5 months, with few manageable haematological toxicities. Fotemustine was safe and effective as second-line chemotherapy in recurrent glioblastoma.
|
Authors | Maria Grazia Fabrini, Giovanni Silvano, Ivan Lolli, Franco Perrone, Annarita Marsella, Valerio Scotti, Luca Cionini |
Journal | Journal of neuro-oncology
(J Neurooncol)
Vol. 92
Issue 1
Pg. 79-86
(Mar 2009)
ISSN: 0167-594X [Print] United States |
PMID | 19018476
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- Organophosphorus Compounds
- fotemustine
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Brain Neoplasms
(drug therapy, mortality)
- Disease-Free Survival
- Female
- Glioblastoma
(drug therapy, mortality)
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy, mortality)
- Nitrosourea Compounds
(therapeutic use)
- Organophosphorus Compounds
(therapeutic use)
|